- Home
- SCNI vs REVB Comparison
SCNI vs REVB Comparison
Compare SCNI & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCNI
- REVB
- Stock Information
- Founded
- SCNI 2003
- REVB 2020
- Country
- SCNI Israel
- REVB United States
- Employees
- SCNI N/A
- REVB N/A
- Industry
- SCNI Biotechnology: Biological Products (No Diagnostic Substances)
- REVB Biotechnology: Pharmaceutical Preparations
- Sector
- SCNI Health Care
- REVB Health Care
- Exchange
- SCNI Nasdaq
- REVB Nasdaq
- Market Cap
- SCNI 1.9M
- REVB 2.2M
- IPO Year
- SCNI N/A
- REVB N/A
- Fundamental
- Price
- SCNI $2.55
- REVB $0.86
- Analyst Decision
- SCNI
- REVB
- Analyst Count
- SCNI 0
- REVB 0
- Target Price
- SCNI N/A
- REVB N/A
- AVG Volume (30 Days)
- SCNI 1.1M
- REVB 2.8M
- Earning Date
- SCNI 07-01-2025
- REVB 05-08-2025
- Dividend Yield
- SCNI N/A
- REVB N/A
- EPS Growth
- SCNI N/A
- REVB N/A
- EPS
- SCNI N/A
- REVB N/A
- Revenue
- SCNI $658,000.00
- REVB N/A
- Revenue This Year
- SCNI N/A
- REVB N/A
- Revenue Next Year
- SCNI N/A
- REVB N/A
- P/E Ratio
- SCNI N/A
- REVB N/A
- Revenue Growth
- SCNI N/A
- REVB N/A
- 52 Week Low
- SCNI $1.90
- REVB $0.77
- 52 Week High
- SCNI $8.92
- REVB $60.80
- Technical
- Relative Strength Index (RSI)
- SCNI 46.70
- REVB 20.22
- Support Level
- SCNI $2.32
- REVB $0.78
- Resistance Level
- SCNI $6.18
- REVB $1.15
- Average True Range (ATR)
- SCNI 0.41
- REVB 0.23
- MACD
- SCNI -0.01
- REVB -0.15
- Stochastic Oscillator
- SCNI 8.10
- REVB 3.38
About SCNI Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with a nanosized antibody (NanoAb) pipeline.
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).